Can Auvelity (dextromethorphan 45 mg/bupropion 105 mg) be used to treat agitation in an adult with dementia, and what is the recommended dosing and monitoring?

Auvelity for Dementia-Related Agitation

Auvelity (dextromethorphan/bupropion) is NOT approved for dementia-related agitation and should not be used for this indication. The FDA has only approved Auvelity for major depressive disorder in adults, not for agitation in dementia 1.

Why Auvelity Should Not Be Used

Lack of FDA Approval and Evidence

• Auvelity's FDA indication is strictly limited to major depressive disorder (MDD) in adults 1
• While dextromethorphan-quinidine (a different formulation) showed efficacy for agitation in Alzheimer's disease in one randomized trial 2, Auvelity contains bupropion, not quinidine
• The dextromethorphan-quinidine combination demonstrated significant reduction in agitation scores (NPI Agitation/Aggression scores reduced from 7.1 to 3.8 vs. 7.0 to 5.3 with placebo) 2, but this evidence cannot be extrapolated to the dextromethorphan-bupropion formulation

Safety Concerns in Dementia Population

The elderly dementia population faces specific risks with Auvelity:

• Seizure risk: Bupropion lowers seizure threshold, which is particularly concerning in elderly patients with dementia who may have underlying brain pathology 1
• Hypertension: Blood pressure monitoring is required, as Auvelity can elevate blood pressure 1
• Drug interactions: Many dementia patients take multiple medications; bupropion is a CYP2D6 inhibitor that can interact with commonly prescribed drugs 1
• Cognitive effects: The impact on cognition in dementia patients is unknown

Guideline-Recommended Approach to Dementia-Related Agitation

Step 1: Comprehensive Assessment

Before any pharmacological intervention 3:

• Assess type, frequency, severity, pattern, and timing of agitation symptoms
• Screen for pain and other modifiable contributors (infections, constipation, medication side effects, environmental triggers)
• Identify dementia subtype, as this influences treatment choices

Step 2: Nonpharmacological Interventions First

Nonpharmacological strategies must be attempted before any medication 3, 4:

• Identify and remove behavioral triggers
• Simplify the environment and establish structured routines
• Educate caregivers on communication techniques (calm tones, simple commands, avoiding confrontation)
• Create meaningful activities tailored to patient interests
• Address safety concerns proactively

Step 3: When Pharmacological Treatment Is Warranted

Medications should only be considered when 3:

• Symptoms are severe, dangerous, and/or cause significant distress to the patient
• Nonpharmacological interventions have been inadequate
• There is documented risk of harm to self or others

Step 4: Appropriate Medication Options

If medication is necessary after the above steps:

Evidence-supported options include:

• Risperidone: Strongest evidence for efficacy (OR 1.96 vs. placebo) 5, but carries cerebrovascular and mortality risks
• Brexpiprazole: FDA-approved specifically for agitation in Alzheimer's dementia with favorable safety profile 6, 7
• Citalopram: Selective serotonin reuptake inhibitors as a class showed efficacy (OR 1.61) 5, with better safety profile than antipsychotics
• Dextromethorphan-quinidine (not Auvelity): Showed efficacy (OR 3.04) 5 but based on limited data

Critical prescribing principles 3:

• Start at low dose and titrate to minimum effective dose
• Obtain informed consent from patient (if feasible) and surrogate decision maker, discussing risks vs. benefits
• Monitor with quantitative measures (e.g., NPI Agitation/Aggression scale)
• If no response after 4 weeks at adequate dose, taper and discontinue
• Attempt dose reduction or discontinuation periodically, as symptoms may resolve over time

Common Pitfalls to Avoid

1. Do not use Auvelity off-label for dementia agitation—it lacks evidence and approval for this indication
2. Never skip nonpharmacological interventions—guidelines emphasize these must be attempted first 3, 4
3. Avoid haloperidol—evidence shows lack of efficacy compared to other options 5
4. Do not continue ineffective medications—reassess after 4 weeks and discontinue if no benefit 3
5. Remember the black box warning—all antipsychotics carry increased mortality risk in elderly dementia patients

Bottom Line

Use evidence-based, guideline-concordant treatments for dementia-related agitation. Auvelity has no role in this indication. Prioritize nonpharmacological interventions, and if medications become necessary, choose agents with demonstrated efficacy and acceptable safety profiles in this specific population (brexpiprazole, risperidone with caution, or citalopram) 3, 5, 7.